Friday, May 28, 2021

May 28, 2021 at 08:51PM Model Informed Drug Development Approaches for Immunogenicity Assessments - 06/09/2021 - 06/09/2021

The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), in collaboration with the Center for Drug Evaluation and Research (CDER), are announcing the following public workshop entitled “Model Informed Drug Development Approaches for Immunogenicity Assessments.”

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3dZmJbG

May 26, 2021 at 08:43PM Remarks by Acting Commissioner Woodcock to the Association for Accessible Medicines 2021Access! Conference - 05/26/2021

Opening Remarks for Association for Accessible Medicine 2021 Access! 2021 conference, Dr. Janet Woodcock, Acting Commissioner of Food and Drugs
May 26, Washington, DC.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3hVj7en

May 26, 2021 at 07:13PM Health Fraud Scams

Learn how to spot health fraud and avoid it.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2UElHK2

May 26, 2021 at 03:49PM Remarks by Dr. Woodcock to the FDA Science Forum and introduction of Dr. Fauci - 05/26/2021

Remarks by Janet Woodcock, MD, Commissioner of Food and Drugs, FDA Science Forum, May 26, 2021, White Oak, MD

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3wxqFIc

May 26, 2021 at 03:00AM 2021_05 Test Article FT 04

2021_05 Test Article FT 04 Test Article some long description some long description.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3voppXB

May 26, 2021 at 02:52AM 2021_05 Test Article FT 03

2021_05 Test Article some long description some long description.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3fjilWz

May 25, 2021 at 10:13PM Coronavirus (COVID-19) Update: May 25, 2021

Coronavirus (COVID-19) Update: May 25, 2021

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3uifZeV

May 25, 2021 at 07:56PM Patient Engagement & Regenerative Medicine: An FDA CBER Workshop for Patient Advocates - 05/06/2021 - 05/06/2021

FDA is hosting a patient workshop on May 6, 2021. This workshop will bring together patients, caregivers, advocates, and other important stakeholders to discuss ways for patients and their advocates to work with FDA to help advance regenerative medicine for rare and genetic diseases.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3urQHeL

May 25, 2021 at 04:27PM ABBOTT PRISM HIV O Plus

Product approval information for the detection of antibodies to HIV-1 (anti-HIV-1) Groups M and O and/or antibodies to HIV-2 (anti-HIV-2) in human serum and plasma specimens.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2U1fG9n

May 25, 2021 at 04:04PM ABBOTT PRISM HBcore

Product approval information is indicated for :
•Qualitative detection of total antibody to hepatitis B core antigen (anti-HBc) in human serum and plasma
•Screening test for blood and plasma to prevent transmission of hepatitis B virus (HBV) to recipients of blood and blood components

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/39XnKh0

May 25, 2021 at 04:00PM Vaccine and Related Biological Product Guidances

This page contains a listing of vaccine and related biological product guidances

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2Mm0pfA

May 25, 2021 at 04:00PM Emergency Use Authorization for Vaccines to Prevent COVID-19

This is the Guidance for Industry for the Emergency Use Authorization for Vaccines to Prevent COVID-19. , COVID-19, Coronavirus Disease 2019, Vaccines , CBER, Biologics

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3iF3PqC

May 25, 2021 at 02:46PM FY 2019 Report from the Director

Fiscal Year 2019 was an exciting time at CBER, as we continued to conduct important mission-oriented research and approved important new products that protect and improve public health. These included a novel gene therapy, vaccines, treatments for immune deficiencies, and tests for protection of the

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/369ow8Z

May 25, 2021 at 02:05PM ABBOTT PRISM HCV

Product approval information is indicated for for the qualitative detection of antibodies to hepatitis C virus (anti-HCV) in human serum and plasma specimens.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3fj3AmT

May 24, 2021 at 08:38PM Withdrawn - Submitting Type V Drug Master Files to the Center for Biologics Evaluation and Research; Draft Guidance for Industry

Guidance for Submitting Type V Drug Master Files to the Center for Biologics Evaluation and Research.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2NqpvcK

May 24, 2021 at 08:04PM Therapeutic Cloning and Genome Modification

The rapid advances over the past few decades in biotechnologies involving somatic cells and gene therapy offer a great potential in regenerative medicine and for the treatment of genetic defects.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/37SZxbX

May 24, 2021 at 05:01PM CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19

CDER Scientific Reviews Supporting EUA for Therapeutic Products

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3sQrJVz

May 24, 2021 at 03:19PM FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act

Guidance for Industry: FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act


via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2RMbBp8

May 24, 2021 at 02:21PM Bispecific Antibody Development Programs Guidance for Industry

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the
availability of a draft guidance for industry entitled "Bispecific Antibody Development
Programs." This draft guidance provides recommendations to assist industry and other parties
involved in the bispecific antibody drug ..

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/32rJaPv

May 21, 2021 at 07:57PM HCT/P Inspection Information

This is the main page for the CBER HCT/P Inspection Information.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3e8kgdo

May 21, 2021 at 04:28PM CMC and GMP Guidances

This page lists CMC and GMP Guidance documents.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2pNxND1

May 21, 2021 at 04:20PM 2021 Meeting Materials, Vaccines and Related Biological Products Advisory Committee

This is the main page for the CBER 2021 Meeting Materials, Vaccines and Related Biological Products Advisory Committee (VRBPAC).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2LBJJmH

May 21, 2021 at 04:19PM Vaccines and Related Biological Products Advisory Committee June 10, 2021 Meeting Announcement - 06/10/2021 - 06/10/2021

This is the CBER Vaccines and Related Biological Products Advisory Committee June 10, 2021 Meeting Announcement.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3hKZTbg

May 21, 2021 at 01:14PM Procleix Ultrio Elite Assay

•Intended to screen for human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) RNA, and/or hepatitis B virus (HBV) DNA and to detect human immunodeficiency virus type 2 (HIV-2) RNA, in plasma and serum specimens from individual human donors, including donors of whole blood, blood compo

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2H7xYBY

May 21, 2021 at 12:21PM Procleix Ultrio Assay

Product approval information is intended for:

• Use in testing plasma and serum specimens to screen organ donors when specimens are obtained while the donor's heart is still beating, and in testing blood specimens from cadaveric (non-heart-beating) donors.
• Use in testing individual samples from living donors of whole blood, blood components, or source plasma, other living donors and heart-beating organ donors, and for testing individual blood specimens from cadaveric (non-heart-beating) donors.
• Use in testing pools of human plasma comprised of equal aliquots of not more than 16 individual donations from donors of whole blood, blood components, or source plasma.
• Used in conjunction with licensed tests for detecting antibodies to HIV-1, HCV, and hepatitis B core antigen (anti-HBc), and with licensed tests for hepatitis B surface antigen (HBsAg).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/31h9A8h

Thursday, May 20, 2021

May 20, 2021 at 08:00PM ICH Q12: Implementation Considerations for FDA-Regulated Products

ICH Q12: Implementation Considerations for FDA-Regulated Products

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3ytqI9O

May 19, 2021 at 11:45PM FDA In Brief: FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available

FDA authorized undiluted, thawed Pfizer-BioNTech COVID-19 Vaccine vials to be stored in the refrigerator at 2°C to 8°C (35°F to 46°F) for up to 1 month.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3eZVsY4

May 19, 2021 at 10:03PM Administrative Guidances

This page lists Administrative Guidance documents.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2mDKLSn

May 19, 2021 at 09:46PM Procleix Ultrio Plus Assays

Product approval information for:
•Use in testing plasma and serum specimens to screen organ donors when specimens are obtained while the donor's heart is still beating, and in testing blood specimens from cadaveric (non-heart-beating) donors.
•Use in testing individual samples from living donors of whole blood, blood components, or source plasma, other living donors and heart-beating organ donors, and for testing individual blood specimens from cadaveric (non-heart-beating) donors.
•Use in testing pools of human plasma comprised of equal aliquots of not more than 16 individual donations from donors of whole blood, blood components, or source plasma.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/31gnUxM

May 19, 2021 at 02:53PM Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1)

Information Sheet Guidance
for Sponsors, Clinical Investigators, and IRBs

Frequently Asked Questions
Statement of Investigator
(Form FDA 1572) (Revision 1)


via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3bCH2Lz

May 18, 2021 at 09:46PM KEDRAB

• Product approval information is indicated for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrently with a full course of rabies vaccine.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3wksQ1Q

Tuesday, May 18, 2021

May 18, 2021 at 06:11PM Remarks by FDA Acting Commissioner Janet Woodcock to the FDLI Annual Conference - 05/18/2021

Remarks by Janet Woodcock, M.D., Acting Commissioner Food and Drugs to the FDLI Annual Conference, May 18, 2021, Washington, DC

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3waAtre

May 18, 2021 at 02:29PM Exceptions and Alternative Procedures Approved Under 21 CFR 640.120

Title 21 Code of Federal Regulations 640.120(a) - The Director, Center for Biologics Evaluation and Research, may approve an exception or alternative procedures to any requirement in subchapter F (Biologics) of Chapter I (Parts 600 - 680) of title 21 of the Code of Federal Regulations regarding bloo

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2ZCEYhG

Monday, May 17, 2021

May 17, 2021 at 08:29PM FDA Voices on Policy

FDA Voices on Policy

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2wZLu61

May 17, 2021 at 07:47PM Investigational New Drug Applications (INDs) for CBER-Regulated Products

An Investigational New Drug Application (IND) is a request for authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2T1aPqZ

May 17, 2021 at 07:38PM Pandemic Influenza Information

Pandemic influenza (flu) is a significant global public health threat. Preparedness has been recognized as a critical local, national and worldwide priority

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3papWZI

May 17, 2021 at 06:47PM Advancing FDA’s Mission by Targeting Key Areas for Regulatory Science Investment and Innovation

The FARS Report communicates the importance and impact of the FDA’s regulatory science research activities and identifies cross-cutting areas that need sustained or new investment to fulfill the FDA’s mission.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3eSYUUs

May 17, 2021 at 05:33PM Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers

Manufacturing, Supply Chain, and Drug and Biological Product ...Q&A
Covid-19

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2FEiPaC

May 17, 2021 at 05:18PM Blood Products Advisory Committee July 18-19, 2018 Meeting Announcement - 07/17/2018 - 07/18/2018

This is the Meeting Announcement for the July 18-19, 2018, Blood Products Advisory Committee (BPAC) Meeting.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2DTRArJ

May 17, 2021 at 03:06PM COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention

COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3yfeQrL

May 14, 2021 at 09:57PM Towards Longer-Acting Factor VIII Products with Better Purity

A description of Andrey Sarafanov's research program and related publications.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3w38cmD

May 14, 2021 at 08:36PM Cell-specific And Gene-specific Targeting of Gene Therapy Vectors

A description of Jakob Reiser's research program and related publications.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3gAdlMj

May 12, 2021 at 11:50PM Meetings with the Office of Orphan Products Development

Guidance for industry, researchers, patient groups, and FDA staff on meetings with the Office of Orphan Products Development

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3ffP1z3

May 14, 2021 at 02:03AM 2021_05 Test Article FT 02

2021_05 Test Article FT 02 Test Article some long description some long description.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/33EmduK

May 13, 2021 at 12:19AM Early Development Considerations for Innovative Combination Products

Guidance for Industry and FDA Staff -Early Development Considerations for Innovative Combination Products

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2R8CoxZ

May 13, 2021 at 12:14AM Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product

Guidance for Industry and FDA Staff - Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2tWll6C

May 13, 2021 at 12:10AM Application User Fees for Combination Products

Guidance for Industry and FDA Staff - Application User Fees for Combination Products

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3bne1Di

May 12, 2021 at 11:53PM Providing Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions

Draft Guidance for Industry on Providing Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3hkZ5tn

May 13, 2021 at 09:48PM Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA

Draft guidance for industry and FDA Staff: Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2TKf08L

May 13, 2021 at 12:06AM How to Write a Request for Designation (RFD)

Guidance for Industry - How to Write a Request for Designation (RFD)

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3tL5kt9

May 13, 2021 at 12:05AM Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4

Guidance for Industry and FDA Staff: Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2SLiV4d

May 13, 2021 at 12:02AM Classification of Products as Drugs and Devices and Additional Product Classification Issues

Guidance for Industry and FDA Staff: Classification of Products as Drugs and Devices and Additional Product Classification Issues

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2vrkvza

May 12, 2021 at 11:50PM Meetings with the Office of Orphan Products Development

Guidance for industry, researchers, patient groups, and FDA staff on meetings with the Office of Orphan Products Development

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3bHlLk3

May 12, 2021 at 11:46PM Humanitarian Use Device (HUD) Designations

Guidance for Industry and FDA Staff - Humanitarian Use Device (HUD) Designations

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3hBTIpZ

May 13, 2021 at 08:07PM Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry

Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry


via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/340XzTr

May 13, 2021 at 12:22AM Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

Guidance for Industry and FDA Staff - Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3tKeLZM

May 13, 2021 at 03:08PM Information for Blood Establishments Regarding FDA’s Determination that Zika Virus is no Longer a Relevant Transfusion-Transmitted Infection

Page for Information for Blood Establishments Regarding FDA’s Determination that Zika Virus is no Longer a Relevant Transfusion-Transmitted Infection, and Withdrawal of Guidance titled “Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3bpB1l9

May 12, 2021 at 03:12PM Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays

Links to the different types of Donor Screening Assays. A table for each assay is provided with detailed information such as tradename, infectious agent, format, specimen, use, manufacturer, approval date, and STN.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/32MwJh9

May 12, 2021 at 03:56PM Blood Guidances

This page contains a listing of Blood Guidances guidances.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2lznGQ9

May 12, 2021 at 03:21PM Information for Blood Establishments Regarding FDA’s Determination that Zika Virus is no Longer a Relevant Transfusion-Transmitted Infection, and Withdrawal of Guidance titled “Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components”

This is the guidance Information for Blood Establishments Regarding FDA’s Determination that Zika Virus is no Longer a Relevant Transfusion-Transmitted Infection, and Withdrawal of Guidance titled “Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3fawPXH

May 12, 2021 at 01:56PM Blood Establishment Registration and Product Listing

All owners or operators of establishments that manufacture blood products are required to register with the FDA, pursuant to section 510 of the Federal Food, Drug, and Cosmetic Act, unless they are exempt under 21 CFR 607.65

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2Pu1Jih

Tuesday, May 11, 2021

May 11, 2021 at 09:16PM Withdrawn Guidances (Biologics)

This page displays withdrawn CBER guidance documents

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/32fZiGC

May 10, 2021 at 07:30PM Temporada de huracanes: Prepárese

Es importante preparar las provisiones de emergencia y mantener a salvo los alimentos, el agua y los medicamentos antes, durante y después de cualquier cambio climático severo.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3hj2o0m

May 11, 2021 at 08:11PM BeneFIX

Product approval information is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2uaFru5

May 11, 2021 at 01:37PM E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials

International Conference on Harmonisation - Efficacy

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/31pGeld

May 11, 2021 at 02:59PM Q3D(R2) – Guideline for Elemental Impurities

International Council for Harmonisation; Draft Guidance for Industry

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/33Bb6Tf

May 11, 2021 at 02:18PM S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals

S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals ; International Council for Harmonisation; Draft Guidance for Industry; Availability

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3y5gtIk

May 11, 2021 at 02:12PM Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex

International Council for Harmonisation-Quality

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2OXWHdS

May 11, 2021 at 02:07PM Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry

International Council for Harmonisation-Quality

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/33yqeRp

May 11, 2021 at 01:55PM S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals

International Council for Harmonisation - Safety Revision 3

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/33AyCjw

May 11, 2021 at 12:02AM Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions

Answers to frequently asked questions about the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/34jUUa0

May 10, 2021 at 11:05PM Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic

The FDA expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents down to 12 years of age.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2RHxgAC

May 10, 2021 at 10:39PM Pfizer-BioNTech COVID-19 Vaccine

Information about the Pfizer-BioNTech COVID-19 vaccine

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3774pem

Friday, May 7, 2021

May 07, 2021 at 08:16PM YESCARTA (axicabtagene ciloleucel)

YESCARTA is a treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2BbIKEt